<DOC>
	<DOCNO>NCT00568529</DOCNO>
	<brief_summary>The purpose study evaluate efficacy overall survival regimen XELOX ( Xeloda oxaliplatin combination ) patient relapse refractory gastric cancer .</brief_summary>
	<brief_title>Combination Capecitabine Oxaliplatin Patients With Relapsed Refractory Gastric Cancer</brief_title>
	<detailed_description>The result treatment relapse refractory gastric cancer still satisfactory . For moment , combination 5-Fu cisplatin regularly use . Capecitabine Oxaliplatin new generation drug 5-Fu cisplatin . The current study evaluate efficacy toxicity combination .</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>Age 18 70 year Patients histologically confirm , unresectable , recurrent and/or metastatic gastric adenocarcinoma ECOG performance status ≤1 Measurable diseases accord RECIST Relapse refractory firstline chemotherapy Sign ICF , normal laboratory finding : absolute neutrophil count platelet count ≥ 2.0×109/L 80×109/L , respectively , hepatic function ( total serum bilirubin ≤ UNL , transaminases ≤ 1.5 time upper normal limit ) renal function ( calculated creatinine clearance ≥ 60 ml/min ) . Relapse within 6 month adjuvant chemotherapy contain oxaliplatin Have use drug regimen firstline chemotherapy Pregnant lactate woman , serious uncontrolled disease intercurrent infection The evidence CNS metastasis History malignancy except cure basal cell carcinoma skin carcinoma insitu uterine cervix Received chemotherapy regimen metastasis Participated clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>Advanced gastric cancer</keyword>
	<keyword>Response rate</keyword>
	<keyword>Side effect</keyword>
	<keyword>time progression</keyword>
	<keyword>overall survival</keyword>
</DOC>